Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Core Insights - Shanghai Henlius Biotech, Inc. has entered into a licensing agreement with Dr. Reddy's Laboratories for the commercialization of its daratumumab biosimilar HLX15 in 43 countries, including 42 European regions and the U.S. [1][2] - The agreement allows Henlius to receive up to $131.6 million, which includes a$33 million upfront payment and potential milestone payments, along with royalties on annual net sales [2][3] - HLX15 is a fully human anti-CD38 monoclonal antibody developed by Henlius, aimed at treating multiple myeloma, and has shown comparable safety and efficacy to reference products in clinical studies [4][9] Company Overview - Henlius is a global biopharmaceutical company focused on providing high-quality, affordable biologic medicines, particularly in oncology, autoimmune diseases, and ophthalmic diseases [8] - The company has launched six products in China and has four approved for marketing in overseas markets, with a robust pipeline of over 50 molecules [9] - Dr. Reddy's Laboratories is a global pharmaceutical company with a strong focus on oncology and a commitment to providing affordable medicines, operating in over 75 countries [6][7] Strategic Collaboration - The partnership with Dr. Reddy's is expected to enhance the global market competitiveness of both companies in oncology treatment, aiming to improve patient access to advanced biologics [3][4] - Henlius' advanced manufacturing capabilities and Dr. Reddy's extensive commercialization experience are seen as complementary strengths that will facilitate the effective delivery of HLX15 to the U.S. and European markets [3][4] - The collaboration signifies a pivotal moment for Henlius in expanding its global partner network and enhancing its product reach [3][8]